Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $4.0 million.

  • CytomX Therapeutics' Prepaid Assets rose 2228.4% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 2228.4%. This contributed to the annual value of $3.6 million for FY2024, which is 2834.83% down from last year.
  • As of Q3 2025, CytomX Therapeutics' Prepaid Assets stood at $4.0 million, which was up 2228.4% from $4.7 million recorded in Q2 2025.
  • CytomX Therapeutics' Prepaid Assets' 5-year high stood at $7.5 million during Q4 2022, with a 5-year trough of $3.1 million in Q2 2024.
  • For the 5-year period, CytomX Therapeutics' Prepaid Assets averaged around $4.5 million, with its median value being $4.3 million (2021).
  • Its Prepaid Assets has fluctuated over the past 5 years, first plummeted by 4350.54% in 2021, then soared by 7423.57% in 2022.
  • CytomX Therapeutics' Prepaid Assets (Quarter) stood at $4.3 million in 2021, then skyrocketed by 74.24% to $7.5 million in 2022, then tumbled by 33.1% to $5.0 million in 2023, then fell by 28.35% to $3.6 million in 2024, then grew by 10.7% to $4.0 million in 2025.
  • Its Prepaid Assets was $4.0 million in Q3 2025, compared to $4.7 million in Q2 2025 and $4.8 million in Q1 2025.